# Champions Oncology, Inc.: Form 10-Q for the period ended Oct 31, 2016

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2016-12-14
- Accepted by EDGAR: Dec 14, 2016, 16:05 ET
- Period: 2016-10-31
- Accession: 0001628280-16-022031
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000162828016022031/csbr10-q10312016.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000162828016022031/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-10-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2016-08-01 to 2016-10-31 | $1.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2016-05-01 to 2016-10-31 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2016-08-01 to 2016-10-31 | −$493.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2016-05-01 to 2016-10-31 | −$3.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2016-08-01 to 2016-10-31 | −$5.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2016-05-01 to 2016-10-31 | $9.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-08-01 to 2016-10-31 | −$504.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2016-05-01 to 2016-10-31 | −$3.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-08-01 to 2016-10-31 | −$0.05 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2016-05-01 to 2016-10-31 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2016-08-01 to 2016-10-31 | $116.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 6 months, 2016-05-01 to 2016-10-31 | −$2.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2016-05-01 to 2016-10-31 | $30.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-10-31 | $4.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-10-31 | $6.7m | us-gaap:AssetsCurrent |
| Total assets | at 2016-10-31 | $8.0m | us-gaap:Assets |
| Current liabilities | at 2016-10-31 | $4.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-10-31 | $4.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-10-31 | $3.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,093 characters.

*The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report and our most recent annual report for the year ended April 30, 2016, as filed on Form 10-K.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2016, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

### Overview and Recent Developments

We are engaged in the development and sale of advanced technology solutions and products utilized in the development and use of oncology drugs. Utilizing our TumorGraft Technology Platform, we provide select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform facilitates drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.

Our platform provides a novel approach to simulating the results of human clinical trials used in developing oncology drugs. According to a 2013 study conducted by Cutting Edge Information, it can cost up to $100,000 per patient in oncology clinical trials and the typical cost for each phase of development per year increases from approximately $3 million in the pre-clinical setting to approximately $150 million in phase III. Simulating trials before executing them provides benefits to both pharmaceutical companies and patients. Pharmaceutical companies can lower the risk of spending resources on drugs that do not show significant anti-cancer activities and increase the chance that the clinical development path they pursue will be focused on an appropriate patient population and a successful combination with other drugs.

We plan to continue our efforts to expand our TumorGraft Technology Platform in order to expand our TOS program. Our POS program will not be the focus of our growth moving forward.

On June 15, 2016, the Company closed a public offering of 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, the underwriter exercised a partial exercise of the over-allotment option granted to the underwriter to purchase an additional 258,749 shares of its common stock at the public offering price. All of the shares have been offered by the Company. The net proceeds, including the partial exercise of the over-allotment option, was $4.3 million, after deducting the underwriting discount and offering-related expenses of $742,000.

### Liquidity and Capital Resources

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, working capital management, and proceeds from certain private and public offerings of our securities. For the six months ended October 31, 2016, we had a net loss of $3.1 million and net operating cash outflows of $2.6 million. In addition, as of October 31, 2016, we had positive working capital of $2.1 million and cash and cash equivalents on hand of $4.3 million. We have grown our revenues while undertaking significant cost reductions beginning in the fourth quarter of fiscal year 2016, which has reduced our net loss and use of cash in operations to approximately $504,000 and $116,000, respectively, for the current quarter. We believe that our cash and cash equivalents on hand at October 31, 2016 are adequate to fund our operations through at least January 2018.

However, in order for us to continue as a going concern, we need to continue to increase revenues and generate cost savings from operations. In addition, we may need to obtain capital from external sources. If we are unable to maintain our operating levels and cannot obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that could restrict our ability to operate our business.

### Operating Results

The following table summarizes our operating results for the periods presented below (dollars in thousands):

| Operating revenue: | For the Three Months Ended October 31, 2016 | % of Revenue | 2015 | % of Revenue | % Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Personalized oncology solutions | $497 | 11.2% | $486 | 16.4% | 2.3% |
| Translational oncology solutions | 3,960 | 88.8 | 2,485 | 83.6 | 59.4 |
| Total operating revenue | 4,457 | 100.0 | 2,971 | 100.0 | 50.0 |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of personalized oncology solutions | 374 | 8.4 | 568 | 19.1 | 34.2 |
| Cost of translational oncology solutions | 1,829 | 41.0 | 1,443 | 48.6 | 26.7 |
| Research and development | 1,008 | 22.6 | 919 | 30.9 | 9.7 |
| Sales and marketing | 717 | 16.1 | 834 | 28.1 | 14.0 |
| General and administrative | 1,022 | 22.9 | 1,700 | 57.2 | 39.9 |
| Total costs and operating expenses | 4,950 | 111.0 | 5,464 | 183.9 | 9.4 |
| Loss from operations | $(493) | (11.0)% | $(2,493) | (83.9)% | 80.2% |

15

| Operating revenue: | For the Six Months Ended October 31, 2016 | % of Revenue | 2015 | % of Revenue | % Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Personalized oncology solutions | $1,007 | 12.4% | $971 | 16.8% | 3.7% |
| Translational oncology solutions | 7,119 | 87.6 | 4,822 | 83.2 | 47.6 |
| Total operating revenue | 8,126 | 100.0 | 5,793 | 100.0 | 40.3 |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of personalized oncology solutions | 847 | 10.4 | 1,228 | 21.2 | 31.0 |
| Cost of translational oncology solutions | 3,879 | 47.7 | 3,056 | 52.8 | 26.9 |
| Research and development | 2,219 | 27.3 | 2,019 | 34.9 | 9.9 |
| Sales and marketing | 1,643 | 20.2 | 1,863 | 32.2 | 11.8 |
| General and administrative | 2,555 | 31.4 | 3,017 | 52.1 | 15.3 |
| Total costs and operating expenses | 11,143 | 137.0 | 11,183 | 193.2 | 0.4 |
| Loss from operations | $(3,017) | (37.0)% | $(5,390) | (93.2)% | 44.0% |

### Operating Revenues

Operating revenues were $4.5 million and $3.0 million for the three months ended October 31, 2016 and 2015, respectively, an increase of $1.5 million or 50%. Operating revenues were $8.1 million and $5.8 million for the six months ended October 31, 2016 and 2015, respectively, an increase of $2.3 million or 40%.

POS revenues were $497,000 and $486,000 for the three months ended October 31, 2016 and 2015, respectively, an increase of $11,000, or 2.3%. POS revenues were $1 million and $971,000 for the six months ended October 31, 2016 and 2015, respectively, an increase of $36,000 or 3.7%. The increase is the result of growth in our sequencing revenue offset by a decline in implant, panel and drug study revenue.

TOS revenues were $4.0 million and $2.5 million for the three months ended October 31, 2016 and 2015, respectively, an increase of $1.5 million, or 59.4%. TOS revenues were $7.1 million and $4.8 million for the six months ended October 31, 2016 and 2015, respectively, an increase of $2.3 million or 47.6%. The increase is due to the increase in studies signed in prior quarters, both in the number and size, the addition of new customers, and the growth of the platform.

### Cost of Personalized Oncology Solutions

Cost of POS for the three months ended October 31, 2016 and 2015 were $374,000 and $568,000, respectively, a decrease of $194,000, or (34.2%). Cost of POS for the six months ended October 31, 2016 and 2015 was $847,000 and $1.2 million, respectively, a decrease of $381,000 or (31%). For the three months ended October 31, 2016 and 2015, gross margins for POS were 24.8% and (16.9%), respectively. For the six months ended October 31, 2016 and 2015, gross margins for POS were 15.9% and (26.5)%, respectively. The improvement in gross margin is attributed to the increase in higher margin, sequencing revenue, and aggressively managing our lab costs.

### Cost of Translational Oncology Solutions

Cost of TOS for the three months ended October 31, 2016 and 2015 were $1.8 million and $1.4 million, respectively, an increase of $386,000, or 26.7%. Cost of TOS for the six months ended October 31, 2016 and 2015 was $3.9 million and $3.0 million, respectively, an increase of $823,000, or 26.9%. The increase in cost was due to an increase in the number of TOS studies. For the three months ended October 31, 2016 and 2015, gross margins for TOS were 53.8% and 41.9%, respectively. For the six months ended October 31, 2016 and 2015, gross margins for TOS were 45.5% and 36.6%, respectively. Gross margins vary quarterly based on timing differences between expense and revenue recognition. The improvement in gross margin was due to higher TOS revenue leveraged off the fixed cost component of the lab and effective management of the variable lab costs.

### Research and Development

Research and development expenses for the three months ended October 31, 2016 and 2015 were $1.0 million and $919,000, respectively, an increase of $89,000, or 9.7%. Research and development expenses for the six months ended October 31, 2016 and 2015 was $2.2 million and $2.0 million, respectively, an increase of $200,000 or 10%. The increase is primarily due to an increase in salary expense. Research and development is focused on the development and expansion of our TumorGraft Technology Platform. We build our platform primarily through research collaborations and relationships with medical centers and academic institutions.

### Sales and Marketing

Sales and marketing expenses for the three months ended October 31, 2016 and 2015 were $717,000 and $834,000, respectively, a decrease of $117,000, or (14.0%). Sales and marketing expenses for the six months ended October 31, 2016 and 2015 was $1.6 million and $1.9 million, respectively, a decrease of $300,000 or (15.8%). The decrease is due to the consolidation of the sales and marketing resources of the POS and TOS division, including combining both under one commercial business leader.

### General and Administrative

General and administrative expenses for the three months ended October 31, 2016 and 2015 were $1.0 million and $1.7 million, respectively, a decrease of $700,000, or (39.9%). The decrease is primarily due to a decrease of $213,000 in stock compensation expense, along with reductions in legal and audit fees $150,000 and personnel related expenses of $100,000. General and administrative expenses for the six months ended October 31, 2016 and 2015 were $2.6 million and $3.0 million, respectively, a decrease of $400,000 or (13.3%).

### Inflation

Inflation does not have a meaningful impact on the results of our operations.

### Cash Flows

The following discussion relates to the major components of our cash flows:

#### Cash Flows from Operating Activities

Net cash used in operating activities was $2.6 million and $5.1 million for the six months ended October 31, 2016 and 2015, respectively. The reduction in cash burn is the result of revenue growth and aggressive expense management.

#### Cash Flows from Investing Activities

Net cash used in investing activities was $30,000 and $44,000 for the six months ended October 31, 2016 and 2015, respectively. These cash outflows primarily relate to the purchase of property and equipment.

#### Cash Flows from Financing Activities

Net cash provided by/(used in) financing activities was $4.3 million and ($29,000) for the six months ended October 31, 2016 and 2015, respectively. The cash inflows in 2016 relate to The June 2016 Public Offering discussed in Note 4 above.

### Critical Accounting Estimates and Policies

The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to apply methodologies and make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, revenue recognition (replacement of licensed tumors), valuation allowance for deferred tax assets, valuation of goodwill, and stock compensation and warrant assumptions. Actual results could differ from those estimates. The Company’s critical accounting policies are summarized in the Company’s Annual Report on Form 10-K, filed with the SEC on July 29, 2016.

### Off-Balance Sheet Financing

We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.

## Controls and procedures

As filed, 1,604 characters.

### Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our management, with the participation of our Chief Executive Officer and our Vice President, Finance, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Vice President, Finance, have concluded that our disclosure controls and procedures were effective as of October 31, 2016 at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Vice President, Finance, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,265 characters.

**We may not be able to meet our cash requirements beyond January 2018 without reducing the scope of our activities or obtaining additional capital from external sources, and if we are unable to do so, we may not be able to continue as a going concern.**

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, working capital management, and proceeds from certain private and public offerings of our securities. For the six months ended October 31, 2016, we had a net loss of $3.1 million and net operating cash outflows of $2.6 million. In addition, as of October 31, 2016, we had positive working capital of $2.1 million and cash and cash equivalents on hand of $4.3 million. We have grown our revenues while undertaking significant cost reductions beginning in the fourth quarter of fiscal year 2016, which has reduced our net loss and use of cash in operations to approximately $504,000 and $116,000, respectively, for the current quarter. We believe that our cash and cash equivalents on hand at October 31, 2016 are adequate to fund our operations through at least January 2018.

However, in order for us to continue as a going concern, we need to continue to increase revenues and generate cost savings from operations. In addition, we may need to obtain capital from external sources. If we are unable to maintain our operating levels and cannot obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that could restrict our ability to operate our business.

Filed Dec 14, 2016.
Source: SEC EDGAR, the filing index for accession 0001628280-16-022031. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
